J&J Wins Nucynta ER Approval, Targets Chronic Pain Market
This article was originally published in The Pink Sheet Daily
The company plans a push for the extended release formulation of its opioid medication.
You may also be interested in...
A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.
Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.
FDA’s active week included clearing expanded indications for Novartis’s Afinitor Disperz and Janssen’s Nucynta ER.